LOGIN  |  REGISTER
Recursion
C4 Therapeutics

Great Elm Schedules Fiscal 2024 First Quarter Conference Call and Webcast

November 07, 2023 | Last Trade: US$1.85 0.00 0.00

WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“Great Elm”), (NASDAQ: GEG), today announced plans to release financial results for the fiscal quarter ended September 30, 2023, after the close of market trading on Wednesday, November 8, 2023.

Company to Host Conference Call & Webcast

Great Elm will also host a conference call and webcast on Thursday, November 9, 2023, at 8:30 a.m. Eastern Time to discuss its fiscal 2024 first quarter financial results.

All interested parties are invited to participate in the conference call by dialing +1 (888) 440-4537; international callers should dial +1 (646) 960-0669. Participants should enter the Conference ID 2595129 when asked.

A copy of the slide presentation that will be referenced during the conference call, can be found here.

The conference call will be webcast simultaneously and can be accessed here.

About Great Elm Group, Inc.

Great Elm Group, Inc. (NASDAQ: GEG) is a publicly-traded, alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Great Elm Group, Inc. and its subsidiaries currently manage Great Elm Capital Corp., a publicly-traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments. Great Elm Group, Inc.’s website can be found at www.greatelmgroup.com.

Media & Investor Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB